Olema Pharmaceuticals (OLMA) Consolidated Net Income (2020 - 2026)

Olema Pharmaceuticals (OLMA) has reported Consolidated Net Income for 7 consecutive years, with -$145.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Consolidated Net Income fell 358.18% year-over-year to -$145.1 million; the TTM figure through Mar 2026 stood at -$279.8 million (down 32.03% YoY), while the FY2025 annual figure was -$398.1 million, down 190.41% from the prior year.
• Consolidated Net Income slipped to -$145.1 million in Q1 2026 per OLMA's latest filing, from -$46.4 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at -$25.8 million in Q3 2022 and bottomed at -$145.1 million in Q1 2026.
• Historically, Consolidated Net Income has averaged -$50.8 million across 5 years, with a median of -$42.5 million in 2025.
• Annual changes were most pronounced in 2022 — Consolidated Net Income soared 78.22% — and 2026, when it tumbled 358.18%.
• Olema Pharmaceuticals' Consolidated Net Income stood at -$26.6 million in 2022, then fell by 2.1% to -$27.1 million in 2023, then slipped by 24.52% to -$33.8 million in 2024, then tumbled by 37.29% to -$46.4 million in 2025, then plunged by 212.88% to -$145.1 million in 2026.
• Business Quant data shows OLMA's Consolidated Net Income at -$145.1 million in Q1 2026, -$46.4 million in Q4 2025, and -$42.5 million in Q3 2025.